X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sterling Biotech with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STERLING BIOTECH vs CIPLA - Comparison Results

STERLING BIOTECH    Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STERLING BIOTECH CIPLA STERLING BIOTECH/
CIPLA
 
P/E (TTM) x -1.8 44.7 - View Chart
P/BV x 0.1 3.7 1.9% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 STERLING BIOTECH   CIPLA
EQUITY SHARE DATA
    STERLING BIOTECH
Dec-13
CIPLA
Mar-17
STERLING BIOTECH/
CIPLA
5-Yr Chart
Click to enlarge
High Rs11622 1.7%   
Low Rs3458 0.7%   
Sales per share (Unadj.) Rs26.8181.9 14.7%  
Earnings per share (Unadj.) Rs-15.012.9 -116.2%  
Cash flow per share (Unadj.) Rs-5.529.3 -18.6%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs54.9155.7 35.3%  
Shares outstanding (eoy) m267.87804.51 33.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.33.0 8.7%   
Avg P/E ratio x-0.542.0 -1.1%  
P/CF ratio (eoy) x-1.318.4 -6.9%  
Price / Book Value ratio x0.13.5 3.7%  
Dividend payout %015.5 0.0%   
Avg Mkt Cap Rs m1,862434,516 0.4%   
No. of employees `0001.423.0 5.9%   
Total wages/salary Rs m54726,338 2.1%   
Avg. sales/employee Rs Th5,303.36,349.1 83.5%   
Avg. wages/employee Rs Th403.81,143.0 35.3%   
Avg. net profit/employee Rs Th-2,959.0449.3 -658.5%   
INCOME DATA
Net Sales Rs m7,181146,302 4.9%  
Other income Rs m432,287 1.9%   
Total revenues Rs m7,223148,589 4.9%   
Gross profit Rs m94724,758 3.8%  
Depreciation Rs m2,54313,229 19.2%   
Interest Rs m4,3771,594 274.6%   
Profit before tax Rs m-5,93112,222 -48.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1,9241,798 -107.0%   
Profit after tax Rs m-4,00710,354 -38.7%  
Gross profit margin %13.216.9 77.9%  
Effective tax rate %32.414.7 220.6%   
Net profit margin %-55.87.1 -788.4%  
BALANCE SHEET DATA
Current assets Rs m14,33587,370 16.4%   
Current liabilities Rs m49,80933,081 150.6%   
Net working cap to sales %-494.037.1 -1,331.3%  
Current ratio x0.32.6 10.9%  
Inventory Days Days40387 463.9%  
Debtors Days Days17162 273.9%  
Net fixed assets Rs m55,432111,567 49.7%   
Share capital Rs m2681,609 16.7%   
"Free" reserves Rs m13,935123,645 11.3%   
Net worth Rs m14,701125,254 11.7%   
Long term debt Rs m9,47836,454 26.0%   
Total assets Rs m73,988209,532 35.3%  
Interest coverage x-0.48.7 -4.1%   
Debt to equity ratio x0.60.3 221.5%  
Sales to assets ratio x0.10.7 13.9%   
Return on assets %0.55.7 8.8%  
Return on equity %-27.38.3 -329.7%  
Return on capital %-6.48.5 -75.6%  
Exports to sales %25.934.2 75.7%   
Imports to sales %0.28.3 2.0%   
Exports (fob) Rs m1,86050,050 3.7%   
Imports (cif) Rs m1212,203 0.1%   
Fx inflow Rs m1,86051,066 3.6%   
Fx outflow Rs m2517,678 0.1%   
Net fx Rs m1,83533,388 5.5%   
CASH FLOW
From Operations Rs m1,71923,824 7.2%  
From Investments Rs m-3,148-13,127 24.0%  
From Financial Activity Rs m1,426-13,239 -10.8%  
Net Cashflow Rs m-3-2,478 0.1%  

Share Holding

Indian Promoters % 33.9 16.0 211.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.0 12.2 -  
FIIs % 9.9 23.7 41.8%  
ADR/GDR % 16.9 1.1 1,536.4%  
Free float % 39.3 26.2 150.0%  
Shareholders   21,482 161,166 13.3%  
Pledged promoter(s) holding % 55.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STERLING BIOTECH With:   UNICHEM LAB  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  VENUS REMEDIES  

Compare STERLING BIOTECH With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Coal India Stock Rallies 4.2%(Closing)

Indian share markets finished some selling pressure in the final hour of trade to finish flat amid weak European markets.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Tata Chem: Suspension of Haldia Operations Drag Bottomline Lower (Quarterly Results Update - Detailed)

Aug 17, 2017

Interruption at Haldia plant and fire at Lostock facility hits operations during the quarter.

Cipla: Impacted by one offs (Quarterly Results Update - Detailed)

Jun 2, 2016

Cipla has announced its 4QFY16 results. The company has reported 7.6% YoY growth in sales and a decline of 68.9% YoY in net profits. Here is our analysis of the results.

Cipla: Quarter Impacted by One-Offs (Quarterly Results Update - Detailed)

Apr 6, 2016

Cipla has announced its 3QFY16 results. The company has reported 15.3% YoY and 4.7% YoY growth in sales and net profits respectively.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STERLING BIOTECH SHARE PRICE


Aug 17, 2017 (Close)

TRACK STERLING BIOTECH

  • Track your investment in STERLING BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STERLING BIOTECH

STERLING BIOTECH 5-YR ANALYSIS

COMPARE STERLING BIOTECH WITH

MARKET STATS